West Kent Interface Adult Formulary
MTW NHS Trust West Kent CCG

Drug Status Key

  • Preferred
  • Second Line
  • Third Line
  • Specialist Initiation
  • Hospital Only
  • Not Approved for Formulary

Macular oedema

Drug safety update

 August 2017: Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration

NICE Guidance

See drug specific guidance below

Dexamethasone intravitreal implant is recommended as an option for the treatment of macular oedema following branch or central retinal vein occlusion and for treating visual impairment caused by diabetic macular oedema in adults only if their condition has not responded well enough to, or if they cannot have non-corticosteroid therapy. It is for specialist use only and is prescribed according to NICE guidance.

Fluocinolone acetonide intravitreal implant is recommended as an option for treating chronic diabetic macular oedema that is insufficiently responsive to available therapies. It is for specialist use only and is prescribed according to NICE guidance.

Other drugs used for the treatment of macular oedema include aflibercept, faricimab and ranibizumab according to NICE guidance.

Dexamethasone

MHRA Warning Drug Costing £500 - £999 NICE BNF EMC

Fluocinolone acetonide

MHRA Warning Drug Costing > £1000 NICE BNF EMC